Cargando…
Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb
The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546792/ https://www.ncbi.nlm.nih.gov/pubmed/34729094 http://dx.doi.org/10.2903/j.efsa.2021.6910 |
_version_ | 1784590260014940160 |
---|---|
collection | PubMed |
description | The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐cereals, fenhexamid on kiwis, iprovalicarb on lettuces, escaroles/broad‐leaved endives and roman rocket/rucola. EFSA prepared a statement containing a final conclusion on the completeness of the data necessary to support the existing tentative maximum residue levels (MRLs) and indications to risk managers whether or not the tentative MRLs currently established by Regulation (EC) No 396/2005 could be maintained. The statement was circulated to Member States for consultation via a written procedure before finalisation. |
format | Online Article Text |
id | pubmed-8546792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85467922021-11-01 Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb EFSA J Statement The European Commission mandated EFSA to issue a statement concerning confirmatory data that were not submitted by the set deadline by the applicant following Article 12 reviews under Regulation (EC) No 396/2005 for the following substances/commodity combination: 2,4‐d on buckwheat and other pseudo‐cereals, fenhexamid on kiwis, iprovalicarb on lettuces, escaroles/broad‐leaved endives and roman rocket/rucola. EFSA prepared a statement containing a final conclusion on the completeness of the data necessary to support the existing tentative maximum residue levels (MRLs) and indications to risk managers whether or not the tentative MRLs currently established by Regulation (EC) No 396/2005 could be maintained. The statement was circulated to Member States for consultation via a written procedure before finalisation. John Wiley and Sons Inc. 2021-10-26 /pmc/articles/PMC8546792/ /pubmed/34729094 http://dx.doi.org/10.2903/j.efsa.2021.6910 Text en © 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. https://creativecommons.org/licenses/by-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nd/4.0/ (https://creativecommons.org/licenses/by-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made. |
spellingShingle | Statement Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title | Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title_full | Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title_fullStr | Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title_full_unstemmed | Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title_short | Lack of confirmatory data following Article 12 MRL reviews for 2,4‐d, fenhexamid and iprovalicarb |
title_sort | lack of confirmatory data following article 12 mrl reviews for 2,4‐d, fenhexamid and iprovalicarb |
topic | Statement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546792/ https://www.ncbi.nlm.nih.gov/pubmed/34729094 http://dx.doi.org/10.2903/j.efsa.2021.6910 |
work_keys_str_mv | AT lackofconfirmatorydatafollowingarticle12mrlreviewsfor24dfenhexamidandiprovalicarb |